The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha
about
The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domainComplete sequence and comparative analysis of the genome of herpes B virus (Cercopithecine herpesvirus 1) from a rhesus monkeyA herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function.Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2.Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein.A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animalsTranslational control of viral gene expression in eukaryotesHSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.Oncolytic viruses: From bench to bedside with a focus on safety.Experimental approaches for the treatment of malignant gliomas.Second-site mutation outside of the U(S)10-12 domain of Deltagamma(1)34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence.Complementation of vaccinia virus lacking the double-stranded RNA-binding protein gene E3L by human cytomegalovirusAlpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction.In vivo replication of an ICP34.5 second-site suppressor mutant following corneal infection correlates with in vitro regulation of eIF2 alpha phosphorylation.The synergistic effect of IFN-alpha and IFN-gamma against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin.The herpes simplex virus type 1 US11 protein binds the coterminal UL12, UL13, and UL14 RNAs and regulates UL13 expression in vivo.Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.Replication of herpes simplex virus 1 depends on the gamma 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection.Herpesviruses and autophagy: catch me if you can!Herpes simplex virus type 2-mediated disease is reduced in mice lacking RNase LOncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.Mammalian alphaherpesvirus miRNAs.HSV.com: maneuvering the internetworks of viral neuropathogenesis and evasion of the host defenseActivation of NF-kappaB in cells productively infected with HSV-1 depends on activated protein kinase R and plays no apparent role in blocking apoptosis.Selective ablation of virion host shutoff protein RNase activity attenuates herpes simplex virus 2 in mice.The herpes simplex virus 1 Us11 protein inhibits autophagy through its interaction with the protein kinase PKR.First oncolytic virus approved for melanoma immunotherapy.The virion host shutoff RNase plays a key role in blocking the activation of protein kinase R in cells infected with herpes simplex virus 1.Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cellsEnhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cellsLoss of mandibular lymph node integrity is associated with an increase in sensitivity to HSV-1 infection in CD118-deficient miceEvaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.Cells lacking NF-kappaB or in which NF-kappaB is not activated vary with respect to ability to sustain herpes simplex virus 1 replication and are not susceptible to apoptosis induced by a replication-incompetent mutant virus.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.HSV Recombinant Vectors for Gene Therapy.
P2860
Q24292276-2B8D8F38-8F5D-49EE-97AD-E697964113F7Q24675195-6C53F12D-86BC-409D-9E8E-D9E29117E542Q33645237-92112C0A-20B1-49D6-986F-19D1EADF2075Q33755158-D2ACFDEA-B690-4E72-AE2C-75A48B0BEB4CQ33785225-BEE4CA3D-2E6A-46FA-AE98-B16BE18EE1B7Q33826815-8F831DB2-133F-47C2-8161-6CCB118182D4Q33827148-E1DA2AEC-5CE7-4B3C-A27C-532A6377CE57Q33851852-E8408BF3-0B1D-4380-A82D-95041636C996Q33935121-0FFFE1B0-8735-444F-BB9A-5A99758826D3Q33995747-4F0C32A5-5E2C-4FC1-B749-CD62023FD6F1Q34044071-EE6A55FD-5649-4209-BEFE-893F1983D4A3Q34127138-3C718923-CFFA-495D-AF6A-0570A83CFB73Q34328502-E0EF795B-7A4F-466F-9BDF-5984AE2A29BEQ34338614-4925F2F0-111C-4DE1-8EE7-7D1FE7E7909FQ34356255-6D95B62B-E332-46B9-9A4F-4BF9C452EA9EQ34381483-1438AF81-80BF-4263-B10D-BEB7EB1C0DEDQ34858111-AFC6DE22-10D3-4724-B7CE-6D3C81905B8DQ34885415-0706E80D-7609-47C6-8712-4A75C6527CE6Q35000995-E44532F9-AB42-4BC9-AC2C-671C33AE21B0Q35023693-ABEFBD5C-69E9-4240-9287-D2E8BB8C512BQ35123297-C6E06499-B207-47CC-BD79-C25C0DF0C1C4Q35260271-CF3DF222-1312-447D-A87C-B12357B93864Q35809335-9E6E4D65-748B-41F8-89C3-3589A0062C7EQ35945465-9AA63257-21EB-4C8D-92AE-B5B277D7D9E5Q36004674-3DE56492-AE94-4B3B-A267-AC8DC9535F38Q36057726-CE35B415-6202-42EE-96EE-345EFC1D6D1DQ36100226-73E1C586-CA05-48F1-A202-419CE8E1BDD1Q36350435-DFD1146B-44F1-4A5C-A63D-4FA7E1103ED3Q36498155-BE4CE93F-045C-42D0-965F-005FF981BD1FQ36559602-196607FD-9CB9-4654-AC68-6CD368B1A2E8Q36597333-2E8235B1-D10C-44B2-BC7D-56DD70130993Q36667947-67C1DB20-274F-4AD5-B71C-9D0631061E3FQ37007756-A1297D62-A580-418A-AA49-DCD443022A07Q37116149-43FC2949-3414-41EB-89B7-F1FF3A8FD6B0Q37120677-8962EE62-75F3-4ADB-BC24-845383EF1EC9Q37283124-C8B2BBEB-A96C-4736-BFCE-0FA76F9E4814Q37583533-C222000D-85D4-4C6A-9F44-F484ADD32CE4Q37707676-51DCDF4F-1063-48CF-9912-98836D651929Q37718569-9EA3167D-1BE9-4044-8EC5-8C031B12A46FQ37787777-0C69064C-4595-4852-AC95-60591DA0C7E3
P2860
The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@ast
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@en
type
label
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@ast
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@en
prefLabel
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@ast
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@en
P2860
P1433
P1476
The second-site mutation in th ...... phosphorylation of eIF-2alpha
@en
P2093
P2860
P304
P577
1998-09-01T00:00:00Z